Treatment Strategies for Mucocutaneous Leishmaniasis

被引:18
作者
Palumbo, Emilio [1 ]
机构
[1] Hosp Sondrio, Dept Pediat, Sondrio, Italy
关键词
Cutaneous leishmaniasis; Paromomycin; Pentavalent antimonials; Treatment;
D O I
10.4103/0974-777X.62879
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Mucocutaneous is an infection caused by a single celled parasite transmitted by sand fly bites. There are about 20 species of Leishmania that may cause mucocutaneous leishmaniasis. Some Leishmania species are closely linked to humans and are therefore found in cities (L. tropica) whereas some others are more traditionally associated with animal species and therefore considered zoonoses (L. major). The evidence for optimal treatment of mucocutaneous leishmaniasis is patchy. Although the cutaneous form of the disease is often self-limiting, it does result in significant scarring and can spread to more invasive, mucocutaneous disease. Therefore, treatment may be considered to prevent these complications. Drugs for systemic and topical treatment are presented and discussed with regard to their application, use and adverse effects.
引用
收藏
页码:147 / 150
页数:4
相关论文
共 21 条
[1]   Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major [J].
Alrajhi, AA ;
Ibrahim, EA ;
De Vol, EB ;
Khairat, M ;
Faris, RM ;
Maguire, JH .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (12) :891-895
[2]  
Amato V, 1998, ANN DERMATOL VENER, V125, P492
[3]   Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala [J].
Arana, BA ;
Mendoza, CE ;
Rizzo, NR ;
Kroeger, A .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2001, 65 (05) :466-470
[4]   Treatment of cutaneous leishmaniasis among travellers [J].
Blum, J ;
Desjeux, P ;
Schwartz, E ;
Beck, B ;
Hatz, C .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (02) :158-166
[5]   TREATMENT OF OLD-WORLD CUTANEOUS LEISHMANIASIS WITH AMINOSIDINE OINTMENT - RESULTS OF AN OPEN STUDY IN LONDON [J].
BRYCESON, ADM ;
MURPHY, A ;
MOODY, AH .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1994, 88 (02) :226-228
[6]  
D'Ohveira JA, 1997, INT J DERMATOL, V36, P938
[7]   Worldwide increasing risk factors for leishmaniasis [J].
Desjeux, P .
MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 2001, 190 (1-2) :77-79
[8]   Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis [J].
Esfandiarpour, I ;
Alavi, A .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2002, 41 (08) :521-524
[9]   Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate [J].
Faghihi, G ;
Tavakoli-kia, R .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2003, 28 (01) :13-16
[10]  
Gurei Mehmet S., 2000, Journal of the Egyptian Society of Parasitology, V30, P169